CN1065411C - 新型保健营养奶粉及其生产方法 - Google Patents
新型保健营养奶粉及其生产方法 Download PDFInfo
- Publication number
- CN1065411C CN1065411C CN95107805A CN95107805A CN1065411C CN 1065411 C CN1065411 C CN 1065411C CN 95107805 A CN95107805 A CN 95107805A CN 95107805 A CN95107805 A CN 95107805A CN 1065411 C CN1065411 C CN 1065411C
- Authority
- CN
- China
- Prior art keywords
- vit
- gram
- milk powder
- gln
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 38
- 239000008267 milk Substances 0.000 title claims abstract description 38
- 210000004080 milk Anatomy 0.000 title claims abstract description 38
- 239000000843 powder Substances 0.000 title claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 235000016709 nutrition Nutrition 0.000 title description 14
- 230000035764 nutrition Effects 0.000 title description 14
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 26
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 14
- 229940067606 lecithin Drugs 0.000 claims abstract description 14
- 239000000787 lecithin Substances 0.000 claims abstract description 14
- 235000010445 lecithin Nutrition 0.000 claims abstract description 14
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 13
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000654 additive Substances 0.000 claims abstract description 13
- 230000000996 additive effect Effects 0.000 claims abstract description 13
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000005875 quercetin Nutrition 0.000 claims abstract description 13
- 229960001285 quercetin Drugs 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 11
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 235000019197 fats Nutrition 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 229960003080 taurine Drugs 0.000 claims description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 5
- 235000020778 linoleic acid Nutrition 0.000 claims description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 208000034189 Sclerosis Diseases 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 235000013361 beverage Nutrition 0.000 abstract description 2
- -1 epigallocatechin caffeine salt Chemical class 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N (-)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 abstract 1
- 235000008935 nutritious Nutrition 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 12
- 235000013305 food Nutrition 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229940099472 immunoglobulin a Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000002011 intestinal secretion Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000034710 Cerebral arteriovenous malformation Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020466 Hunger Diseases 0.000 description 1
- 241000557133 Hunnemannia fumariifolia Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000002263 Intracranial Arteriovenous Malformations Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 201000000034 arteriovenous malformations of the brain Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供一种新型保健营养奶粉,该奶粉中含有多种维生素、多种微量元素、牛磺酸和多不饱和脂肪酸,并特别含有丙氨酰-左旋-谷氨酰胺或甘氨酰-左旋-谷氨酰胺、豆磷脂、木黄酮、POT复合添加剂、表棓尔茶素棓酸盐、白藜芦酸醇、橡黄素和茶多酚。该奶粉是在鲜奶中加入多种维生素、复合微量元素和植物油等后,均质、灭菌、浓缩后,然后加入甘氨酸-左旋-谷氨酰胺或丙氨酰-左旋-谷氨酰胺、多不饱和脂肪酸、Vit C和牛磺酸后,搅拌均匀喷雾干燥制成奶粉后,再将奶粉送入无菌高效混合机中,分次加入前述豆磷脂等七种添加剂,无菌混合制成。可增强早产儿、胎儿、断乳儿、青少年及中老年免疫功能,增进智力,促进生长发育,减少癌症,预防心脑血管硬化、骨质疏松和延缓衰老。
Description
本发明涉及同系列新型保健营养奶粉及其生产方法,特别涉及添加为胎儿、早产儿、断乳儿、青少年增长智力以及中老年人营养保健防癌的奶粉所必需的营养素,为人工喂养儿提供代替母乳和孕妇、断乳儿、青少年以及中老年人的保健增智营养奶粉及其生产方法。
本发明是将性质稳定且无毒付作用的天然氨基酸中的谷氨酰胺(Glutamine简称Gln:下同)的新型稳定产品:丙氨酰-左旋-谷氨酰胺(丙氨酰-l-Gln)或甘氨酰-左旋-谷氨酰胺(甘氨酰-l-Gln)、豆磷脂、木黄酮、POT复合添加剂、表棓尔茶素棓酸盐、白藜芦酸醇、橡黄素和荼多酚加入在本人1987年开始研制,’94全国发明与专利博览会上获金杯奖的系列奶粉中,能增强免疫功能,增长智力,促进早产儿、婴幼儿生长发育,增进青少年学习力和记忆力,减少中老年人疾病,减慢智力退化,延缓衰老。
一、根据中央卫生部主办的《实用儿科杂志》、《实用外科杂志》等国内外多种研究资料介绍,Gln是为合成人体必需的嘌呤、嘧啶及核苷酸提供氮的前体,是肠道粘膜细胞、淋巴细胞及巨噬细胞等多种快速生长细胞的必需营养物,称为组织特需营养物。还可改善氮平衡,促进肠道粘膜及胰腺生长,为肿瘤化疗提供保护,防止肝脏脂肪变,扩大骨骼肌蛋白合成。Gln又是一种高效能量物质,每克分子完全氧化产生30克分子高能量物质三磷酸腺苷,是肠粘膜细胞能直接应用的能量物质和蛋白合成,手术/感染等应激下,豚道粘膜不能利用糖作能量,必需用Gln作能量来源,因此是其必需的燃料。Gln还是淋巴细胞分化、增生及其功能维持所必需,可保留肠细胞群和淋巴组织,维持肠分泌型免疫球蛋白A,防止细菌附着肠粘膜,Gln缺乏可抑制免疫功能,致使淋巴细胞功能受损,肠道分泌型免疫球蛋白A减少,此抗体和肠壁淋巴细胞有保护机体免受肠道细菌、毒素的侵入的重要作用,当它们受损时,则将有利于肠道细菌、毒素的侵入,因此Gln是重要的肠道免疫调节物,还可直接影响巨噬细胞介导的杀菌作用。因此Gln对增强小儿和老年人的免疫力十分重要,对减少早产儿和人工喂养儿常见的腹泻将发挥非常重要作用。
又据1995年1月《澳大利亚医学杂志》介绍的研究发现“剧烈运动会大幅度减少人体内Gln的含量,而Gln对于人体的免疫系统是至关重要的,Gln减少可削弱免疫反应,使人体处于受感染的危险境地”。他们研究发现:“一次最大运动量之后,Gln的含量平均由每升1244微摩尔,减少到560微摩尔;每天剧烈运动两次的训练有素的士兵组,剧烈运动后Gln含量立即下降,第11天Gln全部大幅度下降,由第一天每升630微摩尔减到328微摩尔,运动结束后,Gln继续下降,直到第16天才恢复正常”。因此将Gln添加到运动员的营养口服液中,可增强运动员的免疫力,减少因运动造成的压力和运动过度的不适。
过去由于Gln很不稳定,易分解产生氨、焦谷氨酸等毒性物,故从未单独应用。近年发现有两种Gln二肽,即丙氨酰-l-Gln和甘氨酰-l-Gln稳定产品,经动物实验和人体临床应用表明:1、在体内能很快分解成Gln,增加血Gln浓度。2、维持和改善体内Gln平衡。3、无不良付作用,人体对Gln口服利用能力很大,长期每目口服50克也能很好耐受而无明显付作用。
据检索:美国专利3,717,470号20.02,1973:摘要是:将谷酰胺酶加入含Gln的食品和饮料中,Gln将水解成谷氨酸而防止转变成焦谷氨酸,根本未提及Gln的专门作用。(此食品中已无Gln)
英国专利申请:2,227,919A:15,08,1990:将多种氨基酸和脂肪制成营养乳济(所举三种配方中,只有一种中含有0-16%的Gln)。其氨基酸只是多种氨基酸的混合液(与现在普遍销售的多种氨基口服液和注射液类似)。此营养乳济是多种氨基酸和多种酯的混合物的共同营养作用,根本未提及氨基酸的单独作用,也没有一句提到Gln的特殊作用或单独功能,更没有提及Gln的稳定产品的利用。
国内未检索到添加Gln的食品。本人于1987年在国家标准颁布前就开始研制婴儿奶粉,1992年在北京通过了国内营养专家的鉴定,一致认为“达到国内先进水平”(附鉴定证书和儿科杂志上的论文等)。现将Gln的稳定产品加入上述奶粉中,不但保留了原来的增强智力,促进生长发育,更可增强免疫功能。
二、经100多人临床实验证明:大豆磷脂有明显降血脂、降过氧化脂质和降低动脉硬化指数、细胞膜老化指数等抗老化效果,磷脂是生物膜的重要组成部分,对渗透作用,氧化磷酸化及生物电均起重要作用,对巨噬细胞吞噬功能和人体淋巴细胞DNA合成均有明显促进作用,人体淋巴细胞在磷脂作用下,淋巴细胞的生成率明显增加。磷脂酰胆碱是合成脂蛋白所需物质,肝内脂肪则以脂蛋白形式转运到肝外,磷脂供给不足则影响脂蛋白形成,肝内脂肪不能运出而发生脂肪肝,服用磷脂有良好保肝作用。由于磷脂是参与细胞代谢与功能的基础,因而它有防止血管硬化、高血压及早发性老年痴呆等全面抗老化作用,是有充分理论和实践依据的。日本学者证明:豆磷脂能使脑细胞活化,神经突触迅速发达,就能提高注意力,增进记忆力,使脑迟顿得到改善,否则20岁的人脑细胞每天10万个左右死亡,年龄越大,脑细胞丧失越多,如果饮食中加适量豆磷脂,就可阻止脑细胞的死亡。美国《临床营养杂志》报道,给冠心病人服用卵磷脂,16周后他们血胆固醇明显下降;脑动脉硬化易导致糖尿病,而糖尿病又容易成为老年迟顿的原因,所以有必要用磷脂来提高胰腺细胞的活性。豆磷脂为豆卵磷脂与少量脑磷脂混合物,其中亚油酸高达57%,是优良的营养补品。
三、木黄酮(Genisein)是大豆中自然生成的化合物、豆腐、豆浆、豆蛋白和豆粉中都含有,日本研究发现它能阻碍癌基因的滋生物。他们对25万人进行研究发现,每天喝豆腐脑的人患胃癌的危险性远远小于那些很少喝或不喝豆腐脑的人。
四、新近研究证明:绿茶及付产品下脚料中含有抗氧自由基能力最强的生物活性物,经分离提取出相关的有效成分,合理配位后,可制成一种新颖的POT复合添加剂,它是一种非酶天然物质,与SOD相比,具有耐热性好的特点,即使在100℃高温下,还具活性,且分子量仅为SOD的七分之一,经B8同位素示踪证明,皮肤吸收仅需5-8分钟。由于它材料来源广泛,成本低,大量基础研究和临床应用证明,它具抗肿瘤、抗辐射、抗衰老、解毒抑菌、改善微循环,提高细胞活力,与机体内源SOD有互补激活作用等,因而广泛用于药物、食品和保健营养品中。
五、美国对绿茶中含的表棓尔茶素棓酸盐(Epigallocatec-hingallate)进行了多年研究发现,这种强有力抗氧化剂可保护老鼠不得肺癌,日本人抽的烟是美国人的2倍,它们肺癌死亡率仅是美国的一半,这同日本人每天喝绿茶密切相关。美国另有人研究,给老鼠吃绿茶,老鼠因紫外线致皮肤癌的危险减少了50%
六、白藜芦酸醇:红色或紫色葡萄以及人工烘干的葡萄干中都含有,日本研究发现,它能减少和降低人体内的脂肪和血液中胆固醇含量,法国人食饱和脂肪至少和美国一样多,由于他们平均每日饮用2-3杯红葡萄酒,他们死于冠心病的比率只有美国国人的40%。
七、橡黄素:红葡萄(酒)还大量含有橡黄素,消化系统中的细菌或发酵缸中酵母对它起作用之前,橡黄素本身似乎不起化学作用,但食用后,橡黄素就可形成一种自然界中强有力的抗癌物质。
八、茶多酚:许多油脂特别是多不饱和脂肪酸放置中均易氧化变质,而失去食用价值。茶多酚是油脂的新型强力抗氧化剂,可延长含油脂食品的保质期,提高这些食品的营养和质量。
以上几种新型添加剂均从绿色食品中获得,多年来人们都在食用,有的人还长期大量食用,均未发现毒付作用,故使用安全只是多数人未能长期使用或食用量不足,没有普遍显示出它们的特殊营养保健作用。若孕妇采用此强化的奶粉,不但能确保胎儿智力发育正常,还可预防先天性佝偻病;断乳儿和青少年经常食用此强化食品,将提高智力,增进记忆力和确保身体健壮成长,并可从小预防高血脂、动脉硬化,使他们成为廿一世纪的大有作为的一代新人。中老年人长期食用,可减慢智力退化,减少心脑血管疾病、糖尿病、早发性老年痴呆、延缓衰老,提高中老年人的生活素质。早期长期食用还可防治骨质疏松症。
本发明的新型保健营养奶粉中,每100克含有:甘氨酰-l-谷氨酰胺(或丙氨酰-l-Gln)2-5克豆磷脂 5-20克 木黄酮 0.1-0.5克POT复合添加剂 0.2-0.4克 表棓尔茶素棓酸盐0.1-0.3克白藜芦酸醇 0.1-0.5克 橡黄素0.03-0.2克茶多酚 0,02-0.2克Vit A 1500-2500iu Vit B1 0.5-1mgVit B2 0.6-1.2mg Vit B6 0.5-1mgVit C 40-60mg Vit D 350-400iu烟酸 4-6mg Vit E 5-10mg叶酸 40-50微克 泛酸 2-4mgVit B12 10-12微克 胆碱 30-40mg生物素 10-20微克 肌醇 40-60牛磺酸 40-60mg Vit K1 30-40微克多不饱和脂肪酸 50-500mg钠 250-290mg 钾 800-950mg钙 250-500mg 磷 125-400mg氯 275-750mg 镁 30-80mg铁 6-10mg 锌 5-7mg铜 0.4-0.5mg 锰 20-30微克碘 25-30微克蛋白质 14-18g 总糖50-56g(有一半为麦芽糊精)脂肪 24-30g(其中亚油酸3-4g)灰分 3.5-4g 水分2.0-2.5g
本发明的上述新型保健营养奶粉的生产中,首先在鲜奶中加入多种维生素和复合微量元素及植物油后,经过均质、瞬间灭菌、浓缩;然后再加入甘氨酰-l-Gln、或丙氨酰-l-Gln、多不饱和脂肪酸、Vit C和牛磺酸,经搅拌均匀后喷雾干燥成奶粉。将奶粉送入无菌高效混合机中,分次加入豆磷脂、木黄酮、POT复合添加剂、表棓尔茶素棓酸盐、白藜芦酸醇、橡黄素和茶多酚,在无菌环境中混合均匀,化验合格后包装。
下面通过几个实施例对本发明进一步说明,下面的实施只是用于说明本发明,而不对本发明起限定作用。
实施例一:
将鲜奶中加入多种维生素和复合微量元素、植物油后均质、灭菌、浓缩后加入甘氨酰-l-Gln或丙氨酰-l-Gln、多不饱和脂肪酸、Vit C和牛磺酸后,搅拌均匀后喷雾干燥,将奶粉送入无菌高效混合机中,分次加入豆磷脂、木醇酮、POT复合添加剂、表尔茶素 酸盐、白藜芦酸醇.橡黄素和茶多酚,在无菌环境中混合均匀,化验合格后包装,制成保健营养中老年奶粉,其100克含:
甘氨酰-l-Gln (或丙氨酰-l-Gln)3克
豆磷脂 10克 木黄酮 0.4克
POT复合添加剂 0.3克 表棓尔茶素棓酸盐0.2克
白藜芦酸醇 0.3克 橡黄素 0.1克
茶多酚 0.1克
Vit A 2000iu Vit B1 0.5mg Vit B2 0.6mg
Vit B8 0.7mg Vit C 40mg Vit D 375iu
烟酸 5mg Vit E 7mg 叶酸 45微克
泛酸 3mg Vit B12 11微克 Vit K1 35微克
肌醇 50微克 胆碱 35mg 生物素 15微克
牛磺酸 50mg 多不饱和脂肪酸 0.2克
蛋白质 15克 脂肪 20克(其中亚油酸4g)
总糖 50克(有一半为麦芽糊精)
灰分 3.75克 水分 2.2克 钠 270mg
钾 875mg 氯 450mg 钙 275mg
磷 250mg 镁 50mg 铁 8mg
锌 6mg 铜 0.4mg 碘 25微克
锰 25微克
上述新型保健营养奶粉符合乳粉I(GB10765-89),亚油酸符合乳粉II(GB10766-89),并加入适量的比乳粉易消化的麦芽糊精代替乳粉II中的部分乳糖。
本发明的新型保健营养中老年奶粉,可增强中老年免疫力,减慢智力退化,减少早发性老年痴呆、脑血管硬化、冠心病,糖尿病、癌症,提高中老年人生活素质、延缓衰老,若早期保持食用,还可预防骨质疏松症。
实施例二:
将实施例一中添加剂豆磷脂、POT复合添加剂和多不饱合脂肪酸适当减量,不加木黄酮、表棓尔茶素棓酸盐、白藜芦酸醇,橡黄素和茶多酚,就可制成人工喂养儿和青少年营养保健奶粉,提高他们智力,增进记忆力和从小预防高血脂、动脉硬化。
实施例三:
将实施例一的新型保健营养奶粉100克加水到1000-1600ml,并加入适量食用调味剂后充分搅拌溶解后,过滤灭菌后密闭分装。就制成运动员等人使用的保健营养果奶和饮料。
实施例四:
将叶酸含量提高到每100克奶粉中含4-5毫克,不加麦芽糊精,就可制成能预防胎儿神经系统先天性畸形、先天性佝偻病的孕妇奶粉。
实施例五:
将铁含量提高到每100克奶粉中含10-12mg,不加麦芽糊精,可制成能预防婴幼儿缺铁性贫血的断乳奶粉。
Claims (2)
1.一种保健营养奶粉,该奶粉每100克含有:
Vit A 1500-2500iu Vit B2 0.5-1mg
Vit B2 0.6-1.2mg Vit B6 0.5-1mg
Vit C 40-60mg Vit D 350-400iu
烟酸4-6mg Vit E 5-10mg
叶酸40-50微克 泛酸2-4mg
Vit B12 10-12微克 胆碱30-40mg
生物素10-20微克 肌醇40-60微克
牛磺酸40-60mg Vit K1 30-40微克
多不饱和脂肪酸: 50-500mg
钠 250-290mg 钾 800-950mg
钙 250-500mg 磷 125-400mg
氯 275-750mg 镁 30-80mg
铁 6-10mg 锌 5-7mg
铜 0.4-0.5mg 锰 20-30微克
碘 25-30微克
蛋白质14-18g 总糖50-56g有一半为麦芽糊精
脂肪 24-30g 其中亚油酸3-4g
灰分 3.5-4g 水分2.0-2.5g
其特征在于该保健营养奶粉还含有:
丙氨酰-l-Gln或甘氨酰-l-Gln 2-5克
豆磷脂 5-20克 木黄酮0.1-0.5克
表 尔茶素 酸盐0.1-0.3克POT复合添加剂0.2-0.4克
白藜芦酸醇 0.1-0.5克 橡黄素0.03-0.2克
茶多酚 0.02克-0.2克
2.如权利要求1所述的奶粉的生产方法:其特征在于在鲜奶中加入多种维生素、复合微量元素添加剂和植物油后,经过均质瞬间灭菌、浓缩,然后加入丙氨酰-l-Gln、或甘氨酰-l-Gln、多不饱和脂肪酸,Vit C和牛磺酸后,搅拌均匀,喷雾干燥而获得奶粉,送入无菌高效混合机中,分次加入豆磷脂、木黄酮、麦尔茶素酸盐、POT复合添加剂,白藜芦酸醇、橡黄素和茶多酚,在无菌条件下混合均匀,化验合格后包装。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95107805A CN1065411C (zh) | 1995-06-18 | 1995-06-18 | 新型保健营养奶粉及其生产方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95107805A CN1065411C (zh) | 1995-06-18 | 1995-06-18 | 新型保健营养奶粉及其生产方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1127070A CN1127070A (zh) | 1996-07-24 |
| CN1065411C true CN1065411C (zh) | 2001-05-09 |
Family
ID=5076450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95107805A Expired - Fee Related CN1065411C (zh) | 1995-06-18 | 1995-06-18 | 新型保健营养奶粉及其生产方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1065411C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101223999B (zh) * | 2008-01-21 | 2011-11-09 | 成都自豪药业有限公司 | 一种全面补充各种人体所需的营养素组合物 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2206230C2 (ru) * | 1997-10-31 | 2003-06-20 | Проутин Текнолоджис Интернэшнл, Инк. | Соевый белковый изолят, обогащенный аглюконизофлавонами (варианты) |
| AT407821B (de) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | Mittel auf der basis von naturstoffen |
| FR2778337B1 (fr) * | 1998-05-05 | 2001-08-31 | Inst Nat Sante Rech Med | Antagonistes des ligands du recepteur des arylhydrocarbures |
| AU2003268599B2 (en) * | 1998-05-05 | 2007-03-15 | Casper, Robert Frederic | Arylhydrocarbon Receptor Ligand Antagonists |
| DE60030845T2 (de) * | 1999-01-29 | 2007-05-03 | Sunstar Inc., Takatsuki | Arzneimittel, lebensmittel und orale zusammensetzungen die stilben-artige verbindungen enthalten |
| JP2001128615A (ja) * | 1999-11-04 | 2001-05-15 | Ajinomoto Co Inc | 乳幼児用調整粉乳 |
| FR2845900B1 (fr) * | 2002-10-16 | 2006-07-21 | Oreal | Composition cosmetique pour prevenir et/ou corriger les desordres fonctionnels de l'unite pilo-sebacee des mammiferes |
| AU2003293977A1 (en) * | 2002-10-16 | 2004-05-04 | L'oreal | Cosmetic composition for preventing and/or correcting the functional disorders of the pilo-sebaceous unit of mammals |
| CN1234371C (zh) * | 2003-01-28 | 2006-01-04 | 马驷 | 纳米铜粉作为制备预防治疗骨质疏松、骨折药物的应用 |
| PL2218342T3 (pl) * | 2003-05-27 | 2019-01-31 | Dsm Ip Assets B.V. | Nowe kompozycje nutraceutyczne i ich zastosowanie |
| JP2009511523A (ja) * | 2005-10-14 | 2009-03-19 | ディーエスエム アイピー アセッツ ビー.ブイ. | レスベラトロールを含むニュートラシューティカル組成物の新規な使用 |
| EP2322158B1 (en) * | 2005-10-26 | 2020-06-10 | Kao Corporation | Resveratrol and/or grape leaf extract for energy metabolism activation |
| US20130095189A1 (en) * | 2011-10-14 | 2013-04-18 | Zeina Jouni | Composition and method of phytonutrients for metabolic programming effects |
| IN2015DN03862A (zh) * | 2012-11-02 | 2015-10-02 | Nutricia Nv | |
| CN104542983A (zh) * | 2014-12-15 | 2015-04-29 | 广东高鑫科技股份有限公司 | 癌症病人辅助治疗配方奶粉及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1088734A (zh) * | 1993-01-01 | 1994-07-06 | 侯润安 | 婴儿强化营养奶粉及其生产方法 |
| CN1099566A (zh) * | 1993-08-30 | 1995-03-08 | 山西省山阴县牧工商联合公司乳品厂 | 一种强化牛奶粉及其生产工艺 |
-
1995
- 1995-06-18 CN CN95107805A patent/CN1065411C/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1088734A (zh) * | 1993-01-01 | 1994-07-06 | 侯润安 | 婴儿强化营养奶粉及其生产方法 |
| CN1099566A (zh) * | 1993-08-30 | 1995-03-08 | 山西省山阴县牧工商联合公司乳品厂 | 一种强化牛奶粉及其生产工艺 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101223999B (zh) * | 2008-01-21 | 2011-11-09 | 成都自豪药业有限公司 | 一种全面补充各种人体所需的营养素组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1127070A (zh) | 1996-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1065411C (zh) | 新型保健营养奶粉及其生产方法 | |
| CN103653170B (zh) | 一种水苏糖益生菌固体饮料 | |
| CN106721843B (zh) | 双菌蛋白固体饮料 | |
| US20040253227A1 (en) | Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery | |
| JP4231208B2 (ja) | 骨粗鬆症の予防のための発酵乳由来の栄養補助食品 | |
| CN110547476B (zh) | 快速补充能量的蛋白组合物 | |
| JPH09191852A (ja) | 健康食品 | |
| RU2259048C2 (ru) | Композиция для получения напитка (варианты) | |
| CN101569410A (zh) | 肿瘤患者用的特膳营养食品 | |
| CN102550677A (zh) | 一种对中老年人具有保健功能的液态乳制品及其生产方法 | |
| CN107258927A (zh) | 一种乳清蛋白固体饮料 | |
| CN107232471A (zh) | 一种营养固体饮料 | |
| JP5922863B2 (ja) | 運動機能改善剤 | |
| JP2005312424A (ja) | ケフィアグレインを用いた発酵産物の製造方法及び当該方法によって得られる発酵産物 | |
| CN101595964B (zh) | 一种菌菇浓汤调味料的加工工艺 | |
| CN107136376A (zh) | 一种大豆蛋白固体饮料 | |
| CN110973645A (zh) | 一种具有脑神经营养作用的蛋白粉 | |
| CN111642566A (zh) | 一种有利于儿童身高和智力发育的羊奶粉 | |
| CN119214189A (zh) | 一种儿童调制乳粉及其制备方法和应用 | |
| CN110663956A (zh) | 术后康复配方粉及其制备方法 | |
| CN110584120A (zh) | 骨健康组合物 | |
| CN114680339A (zh) | 一种改善肌肉衰减延缓衰老的营养补充剂及其应用 | |
| CN114947138A (zh) | 一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 | |
| KR100899556B1 (ko) | 모자반 추출물을 첨가한 기능성 식품 | |
| CN1292232A (zh) | 一种新的功能性双歧盐组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| FG4A | Grant of patent | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |